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Intracranial tuberculous mass lesions treated with
thalidomide in an immunocompetent child from a
low tuberculosis endemic country
A case report
Emanuela Caraffa, MDa, Gianluca Russo, MD, PhDa, Serena Vita, MD, PhDa,
∗
, Miriam Lichtner, MD, PhDb,
Anna Paola Massetti, MD, PhDa, Claudio Maria Mastroianni, MD, PhDb, Vincenzo Vullo, MDa,
Maria Rosa Ciardi, MDa, Camilla Ajassa, MDa
Abstract
Rationale: Tuberculous meningitis is a highly morbid, often fatal disease.
Patient concern: We describe a case of an Italian child.
Diagnoses: we diagnosed early a Tuberculous meningitis complicated by the occurrence of hydrocephalus, stroke, and
paradoxical reaction with brain pseudo-abscesses.
Interventions: The child started readily a specific therapy associated with steroids and thalidomide was introduced fewmonth later.
Outcomes: the patient had a favorable outcome without neurologic sequelae.
Lessons:Despite the prompt specific anti-tubercular and adjuvant corticosteroid therapies, only the addition of thalidomide to the
treatment allow to a favorable clinical outcome.
Abbreviations: ADA= adenosine deaminase activity, CCS= corticosteroid, CNS= central nervous system, CSF= cerebrospinal
fluid, DEXA = dual energy x-ray absorptiometry, EVD = external ventricular drain, HERZ = isoniazid, ethambutol, rifampin,
pyrazinamide daily, HHV-6= human herpesvirus-6, HR= isoniazid, rifampin daily, HRZ= isoniazid, rifampin, pyrazinamide daily, HSV
= herpes simplex virus, LP = lumbar puncture, MRI = magnetic resonance imaging, MTB/RIF = Mycobacterium tuberculosis/
rifampicin, PCR = polymerase chain reaction, TB = tuberculosis, TBM = tuberculous meningitis, TNF-a = tumor necrosis factor-alfa,
TVC = tuberculous cerebral vasculitis.
Keywords: cerebral vasculitis, children, hydrocephalus, thalidomide, tuberculous meningitis
1. Introduction
According to the World Health Organization, in 2015 approxi-
mately 10.5 million cases of tuberculosis (TB) occurred globally,
10% being among children, mainly in resource-limited coun-
tries.[1] Tuberculous meningitis (TBM) represents roughly 1% of
all TB cases and affects primarily 2 to 4 years old children.[2,3] The
diagnosis of TBM could be difficult, mainly because of
paucibacillary nature of the infection of the central nervous system
(CNS). Early diagnosis and prompt treatment are the main
determinants of a good outcome in people with TBM which,
despite an appropriate therapy, accounts for high mortality and
neurologic sequelae.[4] Themost serious complications ofTBMare
hydrocephalus, stroke, and tuberculoma formation occurring up
to 80%of pediatric patients.[5,6] Tuberculous vasculitis and stroke
are more frequent in children, and seem related to the basal
cisternal meningeal reaction, with hemiplegia being the most
frequent clinical-related manifestation.[4] Enlargement of the
existing cerebral tuberculomaor appearance of a new tuberculoma
is due to a paradoxical reaction observed in patients with TBM,
mainly within 3 months after the onset of anti-TB therapy.[7] This
reaction is not related to the efficacy of the ongoing anti-TB
therapy, but it is possibly due to an exaggerate immune response to
Mycobacterium tuberculosis antigens,[8,9] similarly to what
happens in immune reconstitution inflammatory syndrome among
HIV-positive patients.[10,11] Currently, data on the paradoxical
reaction among HIV-negative individuals with TBM are poor.[7]
There is no standard treatment for the paradoxical reactions in
patients with TBM, but in some severe cases, an immune-
modulatory drug, thalidomide, has been used because of its
inhibitory action on tumor necrosis factor-alfa (TNF-a).[12–15]
We present the case of a child affected by TBM inwhom the early
diagnosis and adjuvant treatment with thalidomide allowed a
favorableoutcomedespite theoccurrenceofahydrocephalus, stroke,
and TB pseudo-abscesses that did not respond to standard therapy.
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2. Case description
A 9-year-old Italian girl was admitted to Policlinico Umberto I of
Rome (Italy) because of 1-month history of headache, fatigue,
slight fever, reported weight loss (6kg), and sudden late
appearance of diplopia, vomit, dizziness, and slight sleepiness.
One week before the admission to our hospital, the patient
attended the emergency department of another hospital where a
head computed tomography scan without contrast was reported
as normal and the patient discharged. At the admission to our
hospital, general laboratory examinations (including inflamma-
tory values) were normal, and a fundoscopy examination and a
brain magnetic resonance imaging (MRI) were negative (Fig. 1A),
and an electroencephalogram showed slow focal abnormalities.
The day after the sleepiness increased and slight central facial
nerve palsy appeared and the patient was transferred to the
infectious disease pediatric division. A lumbar puncture (LP) was
performed, showing a clear cerebrospinal fluid (CSF) with
pleocytosis (90% lymphocytes), white blood cell count of
372 cells/mL with lymphocytes predominant, high protein
(1317mg/dL), and low glucose (13mg/dL). The microscopic
examination of CSF, microbiologic culture test for common
bacteria, antigens test for Streptococcus pneumoniae and
Neisseria meningitidis, and polymerase chain reaction (PCR)
for common viruses (herpes simplex virus [HSV]-1, HSV-2,
human herpesvirus-6, cytomegalovirus, Epstein–Barr virus, and
Varicella-Zoster Virus) were negative. Table 1 summarizes CSF
analysis results during the follow-up. The patient had no TB
contact history and chest x-ray was negative. Even though a TB
screening was performed: tuberculosis skin test was negative and
QuantiferonTB-gold in peripheral whole blood (QuantiFERON-
TB© Gold In Tube [QFT-IT]; Cellestis Limited Chadstone, Vic,
Australia) was indeterminate. A PCR for M tuberculosis
(GeneXpert MTB/RIF, Cepheid) on CSF was also negative. On
day 2, due to the persistence of clinical symptoms and the
appearance of patient uncertainty at the clinical coordination
tests, another brain MRI was performed (Fig. 1B,C) showing
hypertensive hydrocephalus and a diffuse leptomeningeal
enhancement of the basal cistern, in particular of the inter-
peduncular cistern. An external ventricular drain (EVD) was
placed by neurosurgeon and a sample of ventricular CSF was
analyzed in comparison to the CSF obtained through a second
LP: a dissociation between samples of cellular and biochemical
parameters was evident (Table 1). The microscopic examination
and the GeneXpert MTB/RIF assay of CSF obtained through LP
were still negative, whereas a nested-PCR amplifying a 123-bp
fragment of the M tuberculosis DNA was positive (Table 1). On
Figure 1. Brain magnetic resonance imaging. At the onset of the symptoms, normal imaging was found (A), after 2 days leptomeningeal enhancement over the
basilar cistern and hydrocephalus were relieved (B, C). Focal areas of signal restriction in correspondence of the left caudate nucleus and of the posterior arm of the
left internal capsule (D) were found, suggesting a tuberculous cerebral vasculitis as a complication.
Table 1
Serial CSF data from lumbar puncture and ventricular drain.
CSF data
Day 1
CSF-LP
Day 9
CSF-LP
Day 14
CSF-LP
Day 18
CSF-LP
Day 18
CSF-VD
Day 21
CSF-LP
Day 21
CSF-VD
Day 27
CSF-LP
Day 27
CSF-VD
Day 40
CSF-LP
Day 52
CSF-LP
Day 96
CSF-LP
Aspect Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear Clear
WBC count/mL 372 919 321 139 62 718 21 628 120 1.025 291 81
Neutrophil, % 4 1.3 9 17 11 6 4 20 15
Lymphocyte, % 90 98 81 74 61 78 78 90 84 91 72 69
Glucose, mg/dL 13 15 13 16 45 16 58 9 41 18 18 32
Protein level, mg/dL 1.317 1.993 3.367 2.083 801 14.444 1.746 >6.000 1.881 2.097 2.512 1.328
Lactic acid, mg/dL 64.9 65.8 56,8 32.4 56.8 25.2 45.1 45.1 44.1 36.9 27
ADA, U/L 18.31 9.18 5.02 10.24 4.05 2.89
Direct Gram stain neg neg neg neg neg neg neg neg neg neg neg neg
PCR M tuberculosis neg pos
∗
neg neg
Culture M tuberculosis neg neg neg neg neg neg neg neg neg neg neg neg
Bacterioscopic
examination for AFB
neg neg neg neg neg neg neg neg neg neg neg neg
ADA= adenosine deaminase activity, AFB= acid-fast bacilli, CSF=cerebral spinal fluid, LP= lumbar puncture, PCR=polymerase chain reaction, VD= ventricular drain.
∗
Mycobacterium tuberculosis nested-PCR was positive, whereas GeneXpert MTB/RIF assay was negative.
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the same CSF sample, a lymphocyte T-CD4 polyfunctional
response pattern was observed, and an adenosine deaminase
activity (ADA) test was positive (18U/L). Thus, a TBM was
suspected and a 4-drug anti-tubercular therapy (rifampicin [R] =
10mg/kg/d, isoniazid [H] = 8mg/kg/d, ethambutol [E] = 25mg/
kg/d, pyrazinamide [Z] = 25mg/kg/d), plus and intravenous
steroids (dexamethasone 4mg every 8hours) was started. A
screening of familial contact was performed and the father was
found having a latent TB infection. After few days of HERZ
regimen, the sleepiness improved, while the diplopia was stable.
On day 27, the patient showed an acute onset of clumsy speech
and a right hemiplegia. A control brainMRI (Fig. 1D) showed “2
focal areas of signal restriction in correspondence of the left
caudate nucleus and of the posterior arm of the left internal
capsule, compatible with tuberculous cerebral vasculitis (TVC).”
Acetylsalicylic acid and enoxaparin were added to the ongoing
treatment. A neurologic rehabilitation was then started and the
clinical conditions of the patients progressively improved. On day
33, the EVD was internalized. On day 74, considering the
disappearance of neurologic symptoms/signs, the patient was
discharged with the recommendation to continue treatment with
HERZ regimen plus betamethasone (1mg/d) and acetylsalicylic
acid, and a follow-up schedule was established. After 3 months of
anti-TB regimen, the patient was readmitted to our division
because of reappearance of slight facial nerve palsy. General
laboratory examinations were normal, whereas a brain MRI
revealed a radiologic deterioration in comparison to previous
MRIs with the appearance of new tuberculomas with perilesional
edemawithin themiddle cerebellar peduncle (Fig. 2A). An LPwas
performed and CSF analysis revealed a reduction of leukocytes
and proteins, with a slight increase of glucose in comparison with
previous CSF analysis, whereas microbiologic examinations were
still negative (Table 1). The HERZ was continued and the
corticosteroid (CCS) dosage increased (dexamethasone 4mg
every 8hours) with progressive improvement of clinical condi-
tion. Two months later (5th month of anti-TB therapy),
ethambutol was stopped and the patient was discharged with
the indication to continue HRZ regimen and prednisone (12.5
mg/d). Two months later (7th month of anti-TB therapy), the
patient began to complain of a worsening low back pain. A
columnMRI revealed recent D9 and L1 somatic fractures; a bone
densitometry examination showed only osteopenia (DEXA:
lumbar z-score -1). According to these features, a cholecalciferol
(vitamin D3), therapy was prescribed as well as the use of an
orthopedic bust. The vertebral fractures, the excess of weight gain
and the appearance of hirsutism showed by the patient were all
related to the long CCS ongoing therapy. After 8-months of anti-
TB therapy, the patient was readmitted to our division because of
the appearance of sleepiness and vomit. General laboratory
examinations were always normal and a brain MRI revealed a
worsening of radiologic features (“increased size and perilesional
edema of the pseudo-abscess involving the cerebellar peduncle”)
(Fig. 2B). Then, CCS was administered at higher dose
(dexamethasone 16mg/d) in association with anti-edema therapy
(Mannitol 100 cc  4/d). Moreover, to strengthen anti-TB
therapy, isoniazid daily dose was increased (up to 10mg/kg/d) for
improving CNS penetration; levofloxacin (18mg/kg/d) and
linezolid (20mg/kg/d) were also added because of their anti-
tubercular activity as well as their good CNS penetration. Finally,
to gradually reduce CCS therapy, after obtaining parental written
informed consent, thalidomide (1.2mg/kg/d) administration was
started. Two weeks later the patient was discharged because of
clinical improvement: CCS dosage was progressively reduced and
then stopped, while thalidomide and HRZ were continued
without evidence of significant clinical or laboratory toxicity.
After 5 months after the introduction of thalidomide therapy
(13th month of anti-TB therapy), a control brain MRI was
improving (“reduction of the lesion’s size, hyper-intensity signal,
and surrounding vasogenic edema”) (Fig. 2C), and the drug was
administered every other day for additional 2 months. An
additional control brain MRI performed showed a further
improvement (Fig. 2D). After 1 month, pyrazinamide was
stopped, while HR regimen was continued until completing 24
months of therapy.
3. Discussion and conclusion
The TBM is the most severe extrapulmonary complication of TB,
associated to high mortality rates and neurologic sequelae.[3,4] It
results from hematogenous spread of primary or postprimary
pulmonary disease, or from the rupture of a sub-ependymal
tubercle into the sub-arachnoid space. The clinical presentation
of TBM may be heterogenous, from pauci symptomatic to
severely symptomatic cases, largely depending on the CNS
localization of tuberculoma or tuberculous pseudo-abscess.
Often, TBM-affected patients attend a doctor because of
headache, seizures, diplopia, and/or other clinical signs related
to increased intracranial pressure.
Figure 2. Brain magnetic resonance imaging. Abscess lesions (0.6–1.3cm) in correspondence of brain stem at the base of the left cerebellar peduncle with
surrounding edema reaction and an increase of diffuse leptomeningeal enhancement of the base and small millimeter abscess collections (A). Volumetric increment
of the back cranial portion of the abscess lesion (B). Five months after the introduction of thalidomide, follow-up (C, D).
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Based on clinical signs, the Medical Research Council
described 3 stages of TBM (Medical Research Council), which
has been shown in numerous series to have considerable
prognostic value.[3,11] stage I (mild cases) is characterized by
fully consciousness and no focal deficits; stage II (moderately
advanced cases) by consciousness but with inattention, confu-
sion, lethargy, and focal neurologic signs such as cranial nerve
palsies; and stage III by stupor or comatose, multiple cranial
nerve palsies, or complete hemiparesis or paralysis. Clinical
manifestations of tuberculoma or tuberculous brain abscess
depend largely on their location, and patients often present with
headache, seizures, papilledema, or other signs of increased
intracranial pressure.
We described a case of TBM in stage III with hydrocephalus,
stroke, and paradoxical reaction with tubercular abscesses where
the prompt diagnosis and the addition of thalidomide to the anti-
TB and steroid therapy allowed a favorable outcome.
The TBM diagnosis is generally difficult, mainly because of the
pauci-bacillary nature of the infection leading to a low sensitivity
of traditional microbiologic methods (microscopic direct exami-
nation and mycobacterial culture).[4]
In the present case, diagnostic suspicion was based on clinical
presentation and basic characteristics of CSF analysis, but not
supported by CNS neuro-radiology at the begin. The diagnosis
was then confirmed by a M tuberculosis nested-PCR supported
by immunologic tools based on intracellular staining of
mononuclear cells from blood and CSF,[16,17] ADA test, and
neuro-radiologic features observed during the follow-up.
Treating TBM is a clinical challenge, because it responds
poorly to conventional TB treatment; moreover, it needs 2 kinds
of treatment: the microbiologic and the inflammatory ones.
The choice of anti-TB combination drugs in TBMmanagement
should consider the bactericidal activity of each drug, as well as
its capacity to penetrate into the CNS, but the optimal drug
regimen and duration of each phase are not clearly established.[3]
Moreover, the individual immunity response may play a major
role in defining the patient outcome.[9] According to a review on
CSF concentration of anti-tuberculosis agents,[18] isoniazid well
penetrates the CSF in a concentration-dependent manner and has
the highest early bactericidal activity; pyrazinamide also achieves
acceptable CSF concentration at ordinary drug dosage, whereas
rifampicin shows relatively poor CSF concentration in a dose-
dependent manner, and ethambutol penetrates poorly into CSF.
Although these evidences related to the CSF concentration, the
WHO recommends to treat pediatric TBM using a 4-drug
(HERZ) regimen for 2 months, followed by a 2-drug (HR)
regimen for 10 months.[19] In our patient, we administered a 4-
drug (HERZ) regimen and, to allow a better CSF concentration
of the drugs, we increased the dosage during the treatment.
Moreover, we added levofloxacin to the anti-TB therapy because
of its potent bactericidal activity and good penetration into CSF
and its relatively safe administration in children affected by
TB.[18] Furthermore, considering the worsening clinical evolution
observed at some points during the follow-up, although there
were no data on mycobacterial susceptibility, we added linezolid
to the treatment because of its good CNS penetration and its
effectiveness in drug-resistant TB cases, including children.[20]
Anti-TB therapy alone does not improve outcome significantly
despite reductions in bacillary load. Microglial cells are the
principal target ofM tuberculosis in CNS and TNF-a released by
microglial infected cells play a crucial role in the pathogenesis of
the infection.[21] In fact, low TNF-a levels result in mycobacterial
overgrowth, whereas high levels may lead to exaggerated
immune reaction and tissue destruction possibly related to
mycobacterial antigen release.[7,21] The addition of CCS to the
anti-TB therapy reduces TBM-related mortality, at least in the
short term,[22] possibly because of its anti-inflammatory effect
that may lead also to reduce intracranial pressure. But long
duration of CCS administration is associated to significant
toxicity, as shown in the present case in which the children had
vertebral fractures, significant weight gain, and hirsutism. At the
same time, a worsening situation was documented by brainMRI.
This was compatible with a paradoxical reaction, which is
defined as the worsening of pre-existing tuberculous lesions and/
or the appearance of new tuberculous lesions in patients whose
clinical symptoms initially improved with anti-TB therapy.[7]
Considering that the paradoxical reaction is related to TNF-a
over-release in the CNS, and to reduce CCS-related toxicity,
thalidomide was added to the therapy leading to a clinical and
radiologic response, as previously reported.[14] Thalidomide has
a strong anti-TNF activity[23,24] and stimulates CD8-T lympho-
cytes that play a protective role during M tuberculosis
infection.[25] Thus, although further studies are needing,
thalidomide, although is off-label, could be considered a safe
adjuvant drug for the management of TBM, at least in clinical
situations in which paradoxical reactions are observed.
In conclusion, we present the case of a 9-year-old Italian
children affected by TBM, complicated by hydrocephalus, stroke,
and tubercular pseudo-abscesses, in which the association of an
immune-modulatory therapy to the anti-TB treatment conducted
to a favorable outcome without neurologic sequelae.
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